Stifel Canada resumed coverage of HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:HLS) with a “Hold” rating and raised its target price to $4.75 from $4.00, reflecting the inclusion of newly licensed cardiovascular drug Nilemdo in its valuation framework. In a company update, Stifel analyst Justin Keywood said recent discussions with management […]
Leede Financial analyst Douglas Loe cut his target on Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:CRDL, NASDAQ:CRDL) to $7.00 from $11.00 while maintaining a “Speculative Buy” after the company released fuller Phase II ARCHER data in acute myocarditis. The 109-patient study, presented at a cardiology meeting in Italy, tested Cardiol’s oral […]
Share
Tweet
Share
